Czech National Bank boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 6.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 415,700 shares of the company's stock after acquiring an additional 25,561 shares during the period. Czech National Bank's holdings in Kenvue were worth $8,875,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also added to or reduced their stakes in the company. State Street Corp grew its position in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after buying an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Kenvue by 8.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares in the last quarter. Holocene Advisors LP grew its holdings in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company's stock worth $321,194,000 after purchasing an additional 5,975,392 shares during the last quarter. M&G PLC increased its position in shares of Kenvue by 538.0% during the third quarter. M&G PLC now owns 4,341,172 shares of the company's stock worth $99,847,000 after purchasing an additional 3,660,730 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company's stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Stock Performance
Shares of KVUE traded down $0.20 during mid-day trading on Wednesday, reaching $20.83. The company had a trading volume of 10,049,953 shares, compared to its average volume of 9,171,817. The stock has a market capitalization of $39.94 billion, a P/E ratio of 37.87, a PEG ratio of 2.02 and a beta of 1.46. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a 50 day moving average of $22.54 and a two-hundred day moving average of $21.65. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business's quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.31 EPS. On average, analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.94%. Kenvue's payout ratio is 149.09%.
Analyst Upgrades and Downgrades
KVUE has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their target price on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday. Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a research note on Monday, December 9th. Barclays upgraded shares of Kenvue to a "hold" rating in a research note on Thursday, December 12th. Finally, Piper Sandler raised Kenvue from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $23.18.
Check Out Our Latest Report on KVUE
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
